🚨 From Bald to Full Head in 36 Weeks: Nektar’s New Drug Shows Hair Growth Breakthrough
The big rally in 2025–2026 for this company has coincided with positive clinical data for its lead asset rezpegaldesleukin and renewed investor interest
How long until a completely bald man grows a full head of hair? Believe it or not, science says it’s possible and hope is real
No more Yun Nam. No more Beijing 101. Time to leave the old remedies behind
36 weeks.
Check out this image:
The top shows the starting point—completely bare scalp.
The bottom shows week 36, with all hair follicles fully reactivated.
This patient, suffering from severe alopecia areata, participated in a clinical trial for a new drug by $Nektar Therapeutics(NKTR)$ called Rezpegaldesleukin—an IL-2 receptor agonist.
It works by targeting and regulating the immune system, effectively switching off the misdirected signals attacking hair follicles. Once the attack stops, the hair grows back on its own.
💊 Rezpegaldesleukin Update
It’s an experimental IL‑2 therapy that boosts regulatory T cells to calm the immune system. Early trials show promise in atopic dermatitis, alopecia areata, and even type 1 diabetes. Phase 2b results report good safety and noticeable clinical improvements. Still under clinical trials, but could be a game changer for autoimmune diseases.
The pace at which medicine is conquering hair loss is faster than most people expect. A future without wigs may be closer than we think.
As of Dec 31, 2025, Nektar had about $245.8 million in cash and marketable securities before including proceeds from a large financing. After factoring in financing in Feb 2026 (a secondary stock offering and ATM sales), the total proceeds added roughly ~$476 million, strengthening the balance sheet.
📊 Cash Runway Estimates
Recent guidance and reports (based on Q3 2025 data) suggested the company’s cash **runway extended into Q2 2027 — meaning they anticipated having sufficient funds to support operations and clinical development through roughly the first half of 2027 without needing additional financing.
Year‑to‑date (YTD) performance has been strong, with gains of ~65–68 % in 2026 so far.
The past 1‑month trend has been mixed, showing some choppiness with minor pullbacks.
MarketBeat
📊 Longer‑Term Performance
Over the past 12 months, NKTR has risen dramatically — with total gains reported at around +470 % to +500 % — a very strong upswing for the year.
@TigerObserver @TigerPM @Tiger_comments @TigerStars @Daily_Discussion
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Nice Sharing 😁 There is hope for the Bota 💪. @Barcode @DiAngel @JC888 @koolgal @Shyon @Aqa
Nektar